- The Antibody Series 2023 attracted over 3000 registered in-person and online members
- 2023 on demand talks are available until September 29th – Login to watch
- Dr Paul Parren will chair The Antibody Series 2024, and will conduct the scientific programme of the fourth The Antibody Series edition, in Madeira Island, Portugal
- Register here for 2024
Porto, Portugal – 13 September 2023: The Antibody Series (TAS), hosted by FairJourney Biologics S.A., leader in the discovery and development of antibodies, today announces Dr Paul Parren as Chairman for the 4th edition of conference, taking place 4th – 6th September 2024 in Madeira Island, Portugal.
Dr Paul Parren is dedicated to translating antibody knowledge into innovative therapeutics and technologies. Holding a PhD in molecular immunology from the University of Amsterdam (1992), Prof. Paul Parren is the founder and CSO at Gyes BV, a start-up company pioneering multispecific antibodies. Moreover, he chairs the board of directors of The Antibody Society, a non-profit trade organization that develops initiatives to forward the antibody field.
The Antibody Series 2023, held in Porto and Vidago Palace, was a very special and successful gathering, marking three days of insightful and innovative discussions in the field of antibody discovery and development. With an impressive audience of over 3,000 members, registered both online and in-person, from around the globe, the conference kicked off with opening keynotes on a Douro River Cruise, on-route to the Palace, followed by two days of cutting-edge exchange of antibody knowledge.
The Antibody Series Organizing Committee would like to say a big thank you to the 2023 Chairman, Dr. Dennis Burton and to the amazing 16 speakers, who enlightened us with their expertise:
Brandon DeKosky, Bryan Briney, Gary Nabel, Gestur Vidarsson, Hans De Haard, Jane Osbourn OBE, Louis Picker, Maartje G. Huijbers PhD, Mark Chiu, Rene Hoet, Sameer Velankar, Simone Oostindie, Tomoyuki Igawa, Victor Greiff and Xiaole Shirley Liu.
Dr Paul Parren announced as Chairman of TAS 2024
Dr Paul Parren is dedicated to translating antibody knowledge into innovative therapeutics and technologies. Holding a PhD in molecular immunology from the University of Amsterdam (1992), Prof. Paul Parren is the founder and CSO at Gyes BV, a start-up company pioneering multispecific antibodies.
